Skip to main
APTO

Aptose Biosciences (APTO) Stock Forecast & Price Target

Aptose Biosciences (APTO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aptose Biosciences Inc demonstrates a promising outlook due to the favorable safety and efficacy results highlighted in the APTIVATE trial for its therapeutics, particularly TUS, which shows potential to enhance existing treatment regimens. The trial results suggest that TUS could significantly improve the standard of care for patients with various oncogenic mutations associated with poor prognoses, indicating strong market prospects for the product. This ongoing investigation strengthens the case for further development and potential commercialization of Aptose's therapies in the oncology sector, addressing critical unmet medical needs.

Bears say

Aptose Biosciences faces significant challenges that may hinder its financial performance, including the potential for failed or inconclusive clinical trials, which could derail advancements in its drug development pipeline. Furthermore, the company's ability to secure adequate funding for progressing its therapies is in question, raising concerns about its financial stability. These factors contribute to a negative outlook on the company's stock, as they could impede achieving its valuation targets.

Aptose Biosciences (APTO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aptose Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aptose Biosciences (APTO) Forecast

Analysts have given Aptose Biosciences (APTO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aptose Biosciences (APTO) has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aptose Biosciences (APTO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.